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Abstract
Background: Genetic variation and rapid evolution are hallmarks of RNA viruses, the result of high mutation rates in RNA
replication and selection of mutants that enhance viral adaptation, including the escape from host immune responses.
Variability is uneven across the genome because mutations resulting in a deleterious effect on viral fitness are restricted.
RNA viruses are thus marked by protein sites permissive to multiple mutations and sites critical to viral structure-function
that are evolutionarily robust and highly conserved. Identification and characterization of the historical dynamics of the
conserved sites have relevance to multiple applications, including potential targets for diagnosis, and prophylactic and
therapeutic purposes.
Methodology/Principal Findings: We describe a large-scale identification and analysis of evolutionarily highly conserved
amino acid sequences of the entire dengue virus (DENV) proteome, with a focus on sequences of 9 amino acids or more,
and thus immune-relevant as potential T-cell determinants. DENV protein sequence data were collected from the NCBI
Entrez protein database in 2005 (9,512 sequences) and again in 2007 (12,404 sequences). Forty-four (44) sequences (pan-
DENV sequences), mainly those of nonstructural proteins and representing ,15% of the DENV polyprotein length, were
identical in 80% or more of all recorded DENV sequences. Of these 44 sequences, 34 (,77%) were present in $95% of
sequences of each DENV type, and 27 (,61%) were conserved in other Flaviviruses. The frequencies of variants of the pan-
DENV sequences were low (0 to ,5%), as compared to variant frequencies of ,60 to ,85% in the non pan-DENV sequence
regions. We further showed that the majority of the conserved sequences were immunologically relevant: 34 contained
numerous predicted human leukocyte antigen (HLA) supertype-restricted peptide sequences, and 26 contained T-cell
determinants identified by studies with HLA-transgenic mice and/or reported to be immunogenic in humans.
Conclusions/Significance: Forty-four (44) pan-DENV sequences of at least 9 amino acids were highly conserved and
identical in 80% or more of all recorded DENV sequences, and the majority were found to be immune-relevant by their
correspondence to known or putative HLA-restricted T-cell determinants. The conservation of these sequences through the
entire recorded DENV genetic history supports their possible value for diagnosis, prophylactic and/or therapeutic
applications. The combination of bioinformatics and experimental approaches applied herein provides a framework for
large-scale and systematic analysis of conserved and variable sequences of other pathogens, in particular, for rapidly
mutating viruses, such as influenza A virus and HIV.
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Introduction
Dengue viruses (DENVs) are mosquito-borne pathogens of the
family Flaviviridae, genus Flavivirus, which are phylogenetically
related to other important human pathogens, such as Yellow fever
(YFV), Japanese encephalitis (JEV), and West Nile (WNV) viruses,
among others. DENVs are enveloped, single-stranded RNA (+)
viruses coding for a polyprotein precursor of approximately 3,400
amino acids, which is cleaved into three structural (capsid, C;
precursor membrane and membrane, prM/M; envelope, E) and
seven nonstructural proteins (NS1, 2a, 2b, 3, 4a, 4b and 5). Viral
replication occurs in the cytoplasm in association with virus-
induced membrane structures and involves the NS proteins. There
are 4 genetically distinct DENV types, referred to as DENV-1 to -
4, with multiple genotypic variants [1,2]. DENVs are transmitted
to humans primarily by Aedes aegypti mosquitoes and cause a wide
range of symptoms from an unapparent or mild dengue fever (DF)
to severe dengue hemorrhagic fever (DHF)/dengue shock
www.plosntds.org 1 August 2008 | Volume 2 | Issue 8 | e272syndrome (DSS) that may be fatal. It is estimated that more than
100 million people are infected each year, with up to several
hundred thousand DHF/DSS cases [3]. To date, there is no
licensed prophylactic vaccine and no specific therapeutic formu-
lation available.
Adaptive immune responses include cellular responses to short
peptides derived from self and foreign proteins by proteolysis. The
peptides are presented to T-cell receptors (TCRs) by major
histocompatibility complex (MHC) molecules, referred to as
human leukocyte antigen (HLA) molecules in humans. HLA class
I and class II molecules bind and present peptides to CD8 and
CD4 T-cells, respectively, that play a critical role in antigen (Ag)-
specific cytotoxic responses and the induction and maintenance of
Ag-specific memory responses [4–6]. Peptides that are recognized
by the T cells and trigger an immune response are referred to as
T-cell determinants. One problem in developing a tetravalent
DENV vaccine is the viral diversity [7], with rather low intra-type,
but high inter-type variability, resulting in type-specific and type
cross-reactive T-cell determinants [8]. This variability of related
structures gives rise to a large number of variant peptide sequences
with one or more amino acid differences that may function as
alternative determinants, or altered peptide ligands [9], and affect
anti-DENV host immunity [10,11]. There is abundant evidence
that interactions of memory T cells with peptide ligands bearing
amino acid substitutions at TCR contact residues may alter T-cell
activation and effector function [9,12–15]. Even a single amino
acid substitution can impair the function of T cells in a variety of
ways, producing profoundly different phenotypes that range from
modified stimulatory function to complete inhibition [14]. These
findings suggest that infection or immunization with multiple
DENV types, as is the case with some tetravalent vaccines, may
lead to T-cell responses to variant peptides that might be
deleterious. There is also the possibility that the altered-ligand
phenomenon and cross-reactive T-cell responses, referred to as
original antigenic sin, may play a role in DHF/DSS [7,11,16,17].
Although the etiology of DHF and DSS is only partially
understood, this consideration may have profound implications
for the safety and efficiency of candidate vaccines.
The objective of this study was to search for sequence regions
conserved across the majority of DENVs and representing potential
immune targets [18].Bioinformatics-based approacheswereused to
(a) extract all DENV sequences available in public databases, (b)
identify and examine the structure-function relationship and
distribution in nature of sequences that are highly conserved in
the majority of DENVs (referred to as pan-DENV sequences), (c)
analyze the variability of DENV sequences, and (d) examine the
immune relevance of the conserved sequences as potential T-cell
determinants that would be applicable to the majority of the human
population worldwide [19]. We have also correlated the conserved
DENV sequences to previously reported T-cell determinants and
further identified novel candidate T-cell determinants by analyzing
HLA-restricted immune responses in HLA transgenic mice.
Methods
Methodology overview
The bioinformatics approaches and rationale for the method-
ology adopted in this study have been previously described [20]
and are summarized in Figure 1.
Data collection and sequence organization
DENV protein sequences were retrieved from the NCBI Entrez
protein database in December 2005, and again in December 2007
for validation purposes, by use of a taxonomy ID search via the
NCBI taxonomy browser [21]. The taxonomy IDs for DENV-1 to
-4 were 11053, 11060, 11069 and 11070, respectively. The data
for 2007 were processed separately from the 2005 dataset, but
using identical procedures.
The sequences of the DENV proteins C, prM, E, NS1, NS2a,
NS2b, NS3, NS4a, NS4b and NS5 were extracted from the
database records (Dataset S1) by multiple sequence alignments,
and application of the known cleavage sites obtained from the
annotation of the GenPept [21] reference polyprotein sequences of
DENV-1 to -4 (AAF59976, P14340, AAM51537, AAG45437,
respectively), and from the literature [22]. Grouping of the
sequences of each DENV type was performed by BLAST [23]
followed by CLUSTALX 1.83 [24] multiple sequence alignments.
Both full-length and partial sequences of each DENV protein were
used for analysis, and identical sequences were not removed from
datasets, unless otherwise indicated. All multiple sequence align-
ments were manually inspected and corrected for misalignments.
Identification of pan-DENV sequences
The DENV protein sequences were examined by a consensus-
sequence based approach [25] to identify sequence fragments that
were common across the 4 types. The consensus sequences for the
proteins of each type (intra-type consensus) were first derived by
multiple sequence alignments to select the predominant residue at
each amino acid position. The 4 intra-type consensus sequences
for a given protein (one from each type) were then aligned to
reveal sequence fragments identical across each of the types that
were at least 9 amino acids long. This minimum length was chosen
because it represents the binding core length of a majority of HLA-
restricted T-cell determinants [26]. Only sequence fragments that
were identical in at least 80% of the sequences of each of the 4
types were retained for further analyses. Peptides with residue X in
the alignment were ignored from the percentage representation
(i.e. frequency) computation. The 80% intra-type representation
cut-off was chosen because 44 of the 46 sequence fragments that
were common across the 4 DENV types exhibited intra-type
representation of $81%, and those two that did not had
significantly lower representation (,56–67%) in one of the 4 types.
Information entropy analysis of pan-DENV sequences
Shannon information entropy [20,27] was used to study the
diversity of DENV protein sequences within each type (intra-type
Author Summary
Dengue viruses (DENVs) circulate in nature as a population
of 4 distinct types, each with multiple genotypes and
variants, and represent an increasing global public health
issue with no prophylactic and therapeutic formulations
currently available. Viral genomes contain sites that are
evolutionarily stable and therefore highly conserved,
presumably because changes in these sites have delete-
rious effects on viral fitness and survival. The identification
and characterization of the historical dynamics of these
sites in DENV have relevance to several applications such
as diagnosis and drug and vaccine development. In this
study, we have identified sequence fragments that were
conserved across the majority of available DENV sequenc-
es, analyzed their historical dynamics, and evaluated their
relevance as candidate vaccine targets, using various
bioinformatics-based methods and immune assay in
human leukocyte antigen (HLA) transgenic mice. This
approach provides a framework for large-scale and
systematic analysis of other human pathogens.
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assess the predicted evolutionary stability of the identified pan-
DENV sequences. All entropy analyses were carried out by using
the in-house developed Antigenic Variability Analyser tool
(AVANA) [28]. For immunological applications, the entropy
measure for antigenic sequences was based on nonamer peptides
[26], centered at any given position in the alignment. Applying
Shannon’s formula, the nonamer peptide entropy H(x) at any
given position x in the alignment was computed by
H(x)~{
X n(x)
i~1
p(i, x) log2 p(i, x)
where p(i, x) is the probability of a particular nonamer peptide i
being centered at position x. The entropy value increases with n(x),
the total number of peptides observed at position x; it is also
sensitive to the relative frequency of the peptides; such that it
decreases when one peptide is clearly dominant (i.e. the position is
conserved). Only sequences that contain a valid amino acid at
position x were used for the entropy computation, and the
alignment gaps were ignored. Although gaps tend to occur in high-
diversity regions, proteins that have a high fraction of gaps have
reduced statistical support, yielding an artificially low entropy
value; for this reason, positions where more than 50% of sequences
contained a gap were discarded. Because of the statistical nature of
the entropy measure, both complete protein and shorter fragment
sequences were used in this computation. The first and last 4
positions in the alignment of each protein were not assigned any
peptide entropy value as they cannot be the center of a nonamer.
In theory, nonamer entropy values can range from 0, for a
completely conserved nonamer peptide in all sequences analyzed,
to 39 (log2 20
9); in practice, however, the upper bound is very
much lower for alignments of closely related sequences. For
finite-size sets of sequences, entropy computations are affected by
the sequence count in the alignment. For an alignment of N
sequences, alignment size bias is proportional to 1/N [29]. This
relationship allows a correction for size bias by applying to each
alignment a statistical adjustment that estimates entropy values
for an infinitely-sized alignment with analogous peptide distribu-
tion. To obtain such an estimate, the alignment was repeatedly
randomly sampled to create smaller alignments of varying size,
whose entropy was measured. At each alignment position, the
entropy of these subset alignments of size N was plotted against
1/N, using a linear regression to extrapolate the entropy estimate
for NR‘. The regression’s coefficient of determination (r
2) was
used as a goodness-of-fit of the resulting estimate. In this study,
size bias correction was applied to all entropy calculations, so
that alignment sequence counts could be ignored in comparisons.
All entropy values reported are therefore infinite-size set
estimates, rather than the values directly computed from the
alignments.
Figure 1. Overview of the bioinformatics and experimental approaches employed for the identification and analysis of the pan-
DENV sequences.
doi:10.1371/journal.pntd.0000272.g001
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Data from information entropy analysis were used to study the
distribution of the representation of nonamer variant peptides in
DENV sequences, within and across the types. For any given
position x in the alignment, the combined representation of all
nonamers, excluding the predominant peptide, was computed.
The predominant nonamer was the peptide that was contained in
the majority of the sequences at the position in the alignment. All
the other peptides that differed by at least one amino acid from the
predominant nonamer were defined as variants.
Functional and structural analyses of pan-DENV
sequences
The known and putative structural and functional properties of
pan-DENV sequences were searched in the literature and by use of
the Prosite [30], via ScanProsite [31], and Pfam [32] databases.
When possible, the sequences were mapped on the three-dimensional
(3-D) structures of available DENV Ag in the PDB database [33] by
use of ICM-Browser version 3.3 (www.molsoft.com). X-ray diffrac-
tion 3-D structures were visualized by use of the Corey, Pauling and
Koltun (cpk) representation in the ICM-Browser.
Identification of pan-DENV sequences common to other
viruses and organisms
Pan-DENV sequences that overlapped at least 9 consecutive
amino acid sequences of other viruses and organisms were
identified by performing BLAST search against viral protein
sequences reported at NCBI (as of July 2007), excluding DENV
sequences (parameters set: limit by Entrez query ‘‘txid10239[Or-
ganism:exp] NOT txid12637[Organism:exp]’’; automatically ad-
just parameters for short sequences option enabled; low-complex-
ity filter disabled; alignments: 20,000), and against protein
sequences of all organisms excluding viruses (parameters set: limit
by Entrez query ‘‘Root[ORGN] NOT Viruses[ORGN] NOT
txid81077[ORGN]’’; automatically adjust parameters for short
sequences option enabled; low-complexity filter disabled; align-
ments: 20,000). The keyword ‘‘NOT txid81077 [ORGN]’’ was
used to remove artificial sequence hits.
Identification of known and predicted pan-DENV HLA
supertype binding sequences
Both literature search and query against the Immune Epitope
Database [34] (www.immuneepitope.org) were performed to detect
reported immunogenic, human T-cell determinants (both class I
and II) of DENV that either fully or partially overlapped with the
pan-DENV sequences. In addition, dedicated algorithms based on
several prediction models were used to identify candidate putative
HLA-binding sequences to multiple HLA class I and II supertype
alleles within the pan-DENV sequences. Putative HLA supertypes
class I-restricted peptides were identified by use of NetCTL [35],
Multipred [36], ARB [37], and class II-restricted peptides by
Multipred and TEPITOPE [38]. Further, the intra-type represen-
tation of the putative T-cell determinants was analyzed.
The NetCTL 1.2 algorithm (www.cbs.dtu.dk/services/
NetCTL/) predicts peptides restricted by 12 HLA class I
supertypes (A1, A2, A3, A24, A26, B7, B8, B27, B39, B44, B58
and B62). The algorithm integrates the predictions of HLA
binding, proteasomal C-terminal cleavage and transport efficiency
by the transporter associated with antigen processing (TAP)
molecules. HLA binding and proteasomal cleavage predictions are
performed by an artificial neural networks (ANN) method, while
TAP transport efficiency is predicted using a weight matrix
method. The parameters used for NetCTL prediction were: 0.15
weight on C terminal cleavage (default), 0.05 weight on TAP
transport efficiency (default), and 0.5 threshold for HLA supertype
binding, which was reported to be optimal (sensitivity (SN), 0.89
and specificity (SP), 0.94) in a large benchmark study containing
more than 800 known class I T-cell determinants [35].
The TEPITOPE software (2000 beta version; courtesy of J.
Hammer) utilizes quantitative matrix-based motifs, obtained from
experimental scanning of the binding of P1-anchored designer
peptides to soluble HLA-DR molecules in in-vitro competition
assays, to predict peptides binding to 25 common HLA-DR alleles
(DRB1*0101, *0102, *0301, *0401, *0402, *0404, *0405, *0410,
*0421, *0701, *0801, *0802, *0804, *0806, *1101, *1104, *1106,
*1107, *1305, *1307, *1311, *1321, *1501, *1502, and
DRB5*0101) [38,39]. The parameters for TEPITOPE predictions
were: 5% quantitative threshold and putative determinants with a
10-fold inhibitory residue included. Nonamer peptides predicted
to bind at least 10 out of the 25 HLA-DR alleles were selected as
putative supertype-restricted determinants.
Multipred (research.i2r.a-star.edu.sg/multipred/) is a computa-
tional system for the prediction of peptides that bind to HLA class I
supertypes A2 and A3 and class II HLA-DR supertype [36]. The
HLA alleles selected to represent these supertypes by Multipred were
as follows: A2 supertype, A*0201, *0202, *0203, *0204, *0205,
*0206, *0207 and *0209; A3 supertype, A*0301, *0302, *1101,
*1102, *3101, *3301 and *6801; DR supertype, DRB1*0101, *0301,
*0401, *0701, *0801, *1101, *1301, and *1501. Hidden Markov
model (HMM) and ANN methods are the predictive models of
Multipred; both have been optimized and show similar performances
[36]. The sum thresholds used for prediction of peptides restricted to
the three HLA supertypes by ANN and HMM methods were: A2,
31.33 (ANN; SN=0.80 and SP=0.83) and 47.08 (HMM; SN=0.80
and SP=0.78); A3, 24.53 (ANN; SN=0.90 and SP=0.95) and
37.58 (HMM; SN=0.80 and SP=0.87); and DR, 23.42 (ANN;
SN=0.90 and SP=0.92) and 51.08 (HMM; SN=0.90 and
SP=1.00). Consensus predictions of the two methods were taken
as final predictions for each HLA supertype.
The ARB matrix method (epitope.liai.org:8080/matrix/matrix_-
prediction.jsp) is based on a matrix of coefficients to predict IC50
values [37]. The HLA class I alleles predicted by ARB were grouped
according to the current supertype classification [19,40] and
supertypes containing more than two alleles were selected, namely
A2 (A*0201, *0202, *0203, *0206, and *6802), A3 (A*0301, *1101,
*3101, *3301 and *6801), B7 (B*0702, A*3501, *5101, *5301, and
*5401), and B44 supertypes (B*4001, *4002, *4402, *4403, and
*4501). The prediction threshold value chosen for optimum
sensitivity and specificity was IC50#1000 nM and nonamer peptides
predicted to bind 3 or more alleles of the supertype were considered
as putative promiscuous HLA supertype-restricted determinants.
ELISpot analysis of HLA-DR restricted determinants in
pan-DENV sequences
All experiments were approved by the Johns Hopkins University
InstitutionalAnimalCare and UseCommittee.MurineH-2classII-
deficient, HLA-DR2 [41], HLA-DR3 [42,43], HLA-DR4 (referred
to as DR4/IE) [44] and HLA-DR4/human CD4 (huCD4) [45,46]
Tg mice were used, bred and maintained in the Johns Hopkins
University School of Medicine Animal Facility. Specific pathogen-
free (SFP) colonies were maintained in a helicobacter-negative mice
facility. The HLA-DR expression of the experimental transgenic
mice was evaluated by flow cytometry.
Mice were immunized subcutaneously at the base of the tail,
twice at two weeks interval, with pools of overlapping peptides
covering the DENV-3 protein (15–17 aa, overlapping by 10–11
aa) (Schafer-N Inc., Copenhagen, Denmark; BEI Resources,
Conserved Sequences of Dengue Viruses
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contained 1 mg of each peptide and were emulsified (1:1) in
TiterMax adjuvant (TiterMax USA, Inc.). An aqueous prepara-
tion of TiterMax (1:1) was used as a negative control. Two weeks
after the second immunization, the mice were sacrificed and HLA-
DR-restricted CD4 T cell reponses were assessed by ex vivo IFN-c
ELISpot assay using CD8-depleted splenocytes. Each target
peptide was tested in duplicate. Spot-forming cell (SFC) counts
were normalized to 10
6 cells. The results were considered
significant when the average SFC minus two standard deviations
(SD) was greater than the average of the background plus two SD;
and the average values were greater than 10 SFC per 10
6
splenocytes. The initial screening assays were performed with
peptide matrices [47], followed by assays with the relevant
individual peptides (Nascimento et al., manuscript in preparation).
Results
Dengue virus type protein datasets
A total of 9,512 and 12,404 complete and partial DENV protein
sequences were collected from the NCBI Entrez protein database
of December 2005 and 2007, respectively, representing an
increase of approximately 30% (2892 sequences) in the 24-months
interval (Table 1). The total number of sequences (2007) varied
from 4,011 for DENV-2 to 1,415 for DENV-4 and from 3,845 for
E to 523 for NS4a proteins. Most of the individual protein
sequences originated from DENV strains that were unique
variants with respect to the entire polyprotein, but were identical
to other strains with respect to individual proteins [48].
Conserved pan-DENV sequences
The consensus-sequence approach [20,25] identified a total of 44
pan-DENV sequences of at least 9 amino acids that were present in
$80% of all sequences of each DENV type for both 2005 and 2007
datasets (Figure 2; Table S1). Strikingly, 34 of the 44 (,77%) were
conserved in $95% of all reported DENV sequences. The size of the
p a n - D E N Vs e q u e n c e sr a n g e df r o m9t o2 2a m i n oa c i d s ,w i t ha
combined size of 514 residues, corresponding approximately to 15%
of the complete DENV polyprotein (,3390 amino acids) (Table 2).
The vast majority (42/44) of the pan-DENV sequences were
localized in the NS proteins, with 17, 12, 7 and 5 sequences found
in NS5, NS3, NS1 and NS4b, respectively, and 1 in the NS4a
protein. Notably, the remaining two pan-DENV sequences were
localized in the E protein. No region of at least 9 amino acids and
conserved in $80% of the sequences of each DENV type was found
in the C, prM, NS2a and NS2b proteins. The largest size of the
combined pan-DENV sequences was in the NS5 protein, represent-
ing a total of 215 amino acid positions covering ,24% of the protein,
followed by NS3, NS1 and NS4b with 122, 74 and 69 amino acid
positions covering ,20, ,21 and ,28% of the corresponding
proteins, respectively. The two pan-DENV sequences in the E
protein had a combined size of only 25 amino acids, corresponding to
,5% of the protein.
In large-scale genomic analyses such as this study, biases may
result from the collection of completely or partially overlapping
redundant sequences, corresponding to identical or highly similar
circulating DENV isolates sequenced by various dengue surveil-
lance programs in different countries. Although to some extent this
redundancy may be accepted as a reflection of the incidence of the
corresponding DENV isolates in nature, we assessed its potential
bias effect by repeating the analysis of conservation after discarding
duplicate sequences from the datasets. The analysis of unique
sequences identified all the pan-DENV sequences that were
identified when including duplicates (Figure 2), except for
NS112–20, NS125–35 and NS5597–616. Therefore, the presence of
duplicates in the DENV datasets did not significantly affect the
results. Although the removal of duplicates does not fully
compensate for biases in the datasets, the removal of highly similar
sequences, which may have been generated from relatively large
sequencing efforts in single outbreaks, was deemed undesirable,
since such arbitrary selection would introduce additional biases.
Evolutionary diversity of DENV protein nonamer peptide
sequences
The evolutionary diversity of each DENV type, and the 4 types
combined, was studied by use of Shannon information entropy
Table 1. Number and distribution of reported DENV protein sequences.
DENV
protein
b No. of sequences
a
DENV-1 DENV-2 DENV-3 DENV-4 Total
2005 2007 2005 2007 2005 2007 2005 2007 2005 2007 Increase
C 194 298 266 311 414 547 117 122 991 1278 287
prM 206 311 353 404 458 590 207 225 1224 1530 306
E 852 1051 1277 1518 716 910 338 366 3183 3845 662
NS1 410 565 640 752 201 308 142 159 1393 1784 391
NS2a 150 238 132 173 90 169 121 125 493 705 212
NS2b 136 224 130 163 104 183 40 44 410 614 204
NS3 98 186 145 178 216 297 30 34 489 695 206
NS4a 91 178 128 162 70 151 28 32 317 523 206
NS4b 89 176 129 163 70 150 109 113 397 602 205
NS5 92 179 151 187 181 267 191 195 615 828 213
Total 2318 3406 3351 4011 2520 3572 1323 1415 9512 12404 2892
aCollected from the NCBI Entrez protein database
bManually processed after multiple sequence alignments and use of the known DENV cleavage sites
doi:10.1371/journal.pntd.0000272.t001
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www.plosntds.org 5 August 2008 | Volume 2 | Issue 8 | e272Figure 2. Pan-DENV sequences and their representations in the 4 DENV types. The 44 pan-DENV sequences of at least 9 amino acids that
were found present in $80% of the recorded sequences of each DENV type are shown. The representation values are shown for the 2005 dataset; see
Table S1 for values of both 2005 and 2007 datasets. Amino acid positions were numbered according to the sequence alignments of the 4 DENV types.
The corresponding proteins are indicated on the left.
doi:10.1371/journal.pntd.0000272.g002
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sequences, as described in the Methods. The entropy of the
proteome of the recorded viruses of each type showed numerous
long regions of low entropy (#1), reflecting the relatively high
degree of intra-type sequence conservation, in particular in the
NS3, NS4b and NS5 proteins (Figure 3A–D). Overall, the
average intra-type nonamer entropy values of the individual
protein sequences of DENV-1, -2, -3 and -4 ranged from 0.2 for
the DENV-4 NS4b to 1.0 for DENV-2 prM (Figure S1). Of note,
however, were the marked differences in the relative degree of
entropy of each protein between the 4 DENV types. For example,
NS4b had the least diversity of the proteins of 3 types, but was
replaced in DENV-2 by NS2b, which was the second most
variable in DENV-3. The consequence of the differences in the
sequences of each protein between the 4 types was a marked
increase in the peptide entropy across the DENV 1-4 proteomes
(Figure 3E), with average peptide entropy ranging from 1.6 for
NS3 to 2.6 for NS2a (Figure S1), except for 44 sharply defined
regions of low nonamer entropy (#0.5) where the sequences were
highly conserved in all DENVs (Figure 3E), with no significant
difference between the 2005 and 2007 datasets (Table S2).
Majority of the pan-DENV sequences had entropy values of #0.3,
corresponding to the intra-type representation of $90%. Thus,
the congruent consensus- and entropy-based analyses of the
DENV nonamer peptides revealed highly conserved and evolu-
tionarily stable pan-DENV sequences distributed in several viral
proteins, despite the marked viral diversity defining multiple
DENV types, genotypes and variants [49].
Representation of DENV variant nonamer peptide
sequences
The combined representation of variant peptides that differed by
at least one amino acid from the predominant peptide was also
Table 2. Distribution and size of the pan-DENV sequences.
DENV
protein Size (aa) Pan-DENV sequences
a
No. Size
b % of protein
c
C 113–115 0 0 0
prM 166 0 0 0
E 493–495 2 25 5
NS1 352 7 74 21
NS2a 218 0 0 0
NS2b 130 0 0 0
NS3 618–619 12 122 20
NS4a 150 1 9 6
NS4b 245–249 5 69 28
NS5 900–904 17 215 24
Total 3387–3398 44 514 15
aSequences of at least 9 amino acids that were represented in $80% of all
DENV sequences of each type
bCombined amino acid size of all pan-DENV sequences in the protein
cPercentage of the combined pan-DENV sequence size over that of the
corresponding protein size
doi:10.1371/journal.pntd.0000272.t002
Figure 3. Shannon entropy of nonamer peptides within and across DENV types sequences. The entropy values were computed from the
alignments of DENV sequences using the Antigenic Variability Analyzer software, as described in the Methods. Values were plotted for DENV-1 (A),
DENV-2 (B), DENV-3 (C), DENV-4 (D), and all 4 DENV types (E) sequences (2005 dataset). Entropy values around protein cleavage sites are non
significant, since the corresponding positions cannot be the center of a nonamer (see Methods). The triangles below indicate the locations of the pan-
DENV sequences in the corresponding proteins.
doi:10.1371/journal.pntd.0000272.g003
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DENV-3 proteins are shown in Table 3.N o n a m e r st h a tl a c k
entropy (zero entropy) have one sequence in all of the recorded virus
isolates, and therefore have no variants. Positions with high entropy
can contain many different variant peptides, each at lesser (or equal)
frequency than the predominant peptide. The combined represen-
tation of variant peptides at each nonamer position across the
proteome of each individual DENV type was generally low,
representing less than 10% of the corresponding sequences, except
for some positions where it was more than 50% (Figure 4A–D).
Notably, the nonamer position with the highest combined variant
representation for each DENV type was found in the nonstructural
proteins and not the structural ones, with representation values
ranging from ,61 to ,78% (DENV-1 NS5, DENV-2 NS5, DENV-
3NS2a,andDENV-4NS1andNS3proteins).Whenrepresentations
of variants across all DENVs were calculated, the majority of all
nonamer sites contained variants that together represented ,60–
85% of the total DENV sequences at that site (the highest
representation of ,85% was in the NS1 protein) (Figure 4E). This
was in striking contrast to the 0 to ,5% combined representation of
variants at each nonamer position in the pan-DENV sequences, with
no significant difference between the 2005 and 2007 datasets (Table
S2). The majority of all nonamer sites in the pan-DENV sequences
lacked variant or contained variants that together represented ,1%
of all recorded DENVs. These data further illustrate the extremely
high genetic stability of the 44 pan-DENV sequences, among all
recorded DENV sequences and demonstrate that irrespective of the
high variability between the sequences of the 4 DENV types, the
representation of variants in the pan-DENV sequences was almost
negligible.
Functional and structural correlates of the pan-DENV
sequences
Highly conserved protein sequences are likely to represent critical
sites and domains [50]. A search of the literature and the Prosite and
Pfam databases [30,32] revealed that 27 of the 44 pan-DENV
sequences were associated with biological activities (Table S3); the
functional significance of the remaining 17 pan-DENV sequences
was not known. The two pan-DENV sequences in the E protein
corresponded to the fusion peptide (positions 98 to 110) and
dimerisation domain [51,52]. In NS3, one pan-DENV sequence
corresponded to the peptidase family S7 (Flavivirus serine protease)
domain and comprised the His-51 catalytic residue [53], 3 sequences
corresponded to known/putative Flavivirus Asp-Glu-Ala-Asp/His
(DEAD/H) domain associated with ATP-dependent helicase activity
[54], and two sequences were predicted to be required for cell
attachment and targeting signal for microbodies. In NS5, one pan-
DENV sequence corresponded to the conserved methyltransferase
(MTase) S-adenosyl-L-methionine binding motif I (positons 77–86)
involved in viral RNA capping [55], and two sequences corresponded
to RNA dependent RNA polymerase (RdRp) domain [56].
Furthermore, 6 of the 27 pan-DENV sequences were predicted to
exhibit post-translational modification(s), including N-glycosylation,
protein kinase C and casein kinase II phosphorylation, N-
myristoylation and/or amidation (Table S3).
It is generally recognized that amino acids buried inside proteins
are subject to greater interactions and packing constraints [57]
than those exposed on the outer surface. Although none of the
DENV protein structures in the protein data bank (PDB) [33] was
full-length, 19 of the 44 pan-DENV sequences could be mapped
on the available crystallographic models of the E ectodomain
(Accession No. 1OAN; 394 out of 493–495 residues), NS3 (1BEF
and 2BMF, 181 and 451 out of 618–619 residues, respectively) and
NS5 fragments (1R6A, 295 out of 900–904 residues). Eleven of the
19 pan-DENV sequences were buried, 2 partially exposed and 6
exposed at the surface of the corresponding structures (Figure
S2). However, these results should be considered preliminary until
full-length 3-D structures are available.
Distribution of pan-DENV sequences in nature
Twenty-seven (27) of the 44 pan-DENV sequences overlapped at
least 9 amino acid sequences of as many as 64 other viruses of the
family Flaviviridae, genus Flavivirus (Figure 5). Zika virus shared 22 of
the 27 sequences; Ilheus and Kedougou viruses, 18; and representatives
of some of the significant human pathogens, West Nile, St. Louis
encephalitis, Japanese encephalitis, Yellow fever and Tick-borne encephalitis
viruses, shared from 16 to 9 pan-DENV sequences. Thirteen (13) of
the 27 sequences represented NS5, of which 9 were present in at least
Table 3. Examples of the distribution of variant nonamer peptides in DENV-3.
DENV-3 protein
Nonamer
position
No. of
sequences
Nonamer
peptides
a
Representation of
peptides
Combined % representation
of variants
b
Nonamer
entropy
c
E1 4 4 7 9 DFVEGLSGA 479 (100%) 0 0
NS2a 176 64 LAGISLLPV 25 (39%) 61 2.4
LAGVSLLPV 11 (17%)
LAGVSLLPL 9 (14%)
LAVISLLPV 9 (14%)
LAGISLLPL 6 (9%)
LAGISLFPV 2 (3%)
LAGISLMPV 2 (3%)
NS4a 86 68 SIGLICVVA 39 (57%) 43 1.5
SIGLICVIA 19 (28%)
SIGLICVIV 8 (13%)
SIGLICVAA 2 (3%)
aThe predominant peptide is underlined
bVariants include all the peptides at the position, except the predominant
cEntropy value of all the peptides at the position (predominant peptide included)
doi:10.1371/journal.pntd.0000272.t003
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sequences that contained variant peptides at each nonamer position are shown for DENV-1 (A), DENV-2 (B), DENV-3 (C), DENV-4 (D), and all 4 DENV
types (E) (2005 dataset). Values around protein cleavage sites are non significant (see Figure 3). The triangles below indicate the locations of the pan-
DENV sequences in the corresponding proteins.
doi:10.1371/journal.pntd.0000272.g004
Figure 5. Number of pan-DENV sequences conserved in the different Flaviviruses.
doi:10.1371/journal.pntd.0000272.g005
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35 and 23 species; one E sequence was found in 19 species; and the
remaining were in NS1 and NS4b (Figure 6; Table S4). Five (5) of
the 27 were associated with known biological activities (NS579–90
MTase, NS5658–670 RdRp, NS346–55 peptidase S7, NS3284–292
DEAD/H and E97–111 dimerisation/fusion domains). Interestingly,
two sequences, NS3406–418 and NS5597–616, overlapped 9 amino acid
sequences of the cell fusing agent virus polyprotein-like protein from
the mosquito Aedes albopictus [58], and the phage-related tail fibre
protein-like protein from the bacteria Chromohalobacter salexigens DSM
3043, respectively.
The representation of many of the pan-DENV sequences was
high among known sequences of several of the highly studied
Flaviviruses (Table S4): St. Louis encephalitis, West Nile, Japanese
encephalitis, Murray Valley encephalitis, Usutu, Kokobera, Ilheus, Tick-borne
encephalitis, Langat, Omsk hemorrhagic fever, Louping ill, Powassan,
Kyasanur forest disease and Yellow fever viruses. Protein sequence data
for the rest of the Flaviviruses that shared pan-DENV sequences was
limited (,10 sequences) in the public database. Seven of the 27
pan-DENV sequences, NS112–20, NS3256–267, NS3383–392, NS3491–
499, NS4b223–236, NS56–14 and NS5302–310, were present in a few
species with less than 10 reported total sequences (Table S4).
Known and predicted HLA supertype-restricted, pan-
DENV T-cell determinants
Literature survey and database search revealed that 10 of the
pan-DENV sequences (9 in NS3, one in E) overlapped at least 9
amino acids of 15 previously reported DENV T-cell determinants
immunogenic in human, with their HLA restriction, when known,
showed both class II (DR*15, DPw2) and class I (A*11) specificities
(Table 4). Further evaluation of the immune-relevance of the
pan-DENV sequences included a search for candidate putative
promiscuous HLA supertype-restricted T-cell determinants within
these regions by use of several computational algorithms: NetCTL
[35], Multipred [36], ARB [37] and TEPITOPE [38]. Overall, 34
of 44 (,77%) pan-DENV sequences (Figure 7), identified in the
NS5, NS3, NS1, E and NS4a proteins were predicted to contain
100 supertype-restricted binding nonamers (Table S5). The
majority (88/100) of the predicted promiscuous HLA-binding
nonamers were present in $95% of the sequences of each DENV
type (Table S6). Thirty-one (,91%) of the 34 putative supertype
pan-DENV sequences contained HLA-binding nonamers for
multiple HLA supertypes. Clusters (hotspots) of two or more
overlapping HLA-binder nonamer core peptides were present in
27 (,79%) of the 34 putative supertype pan-DENV sequences.
About half (14/27) of these clusters contained three or more
nonamer binders overlapping by 8 amino acids, covering most or
the entire corresponding conserved region.
Immunogenicity of HLA-DR-restricted pan-DENV
sequences in HLA Tg mice
The immunogenicity of the pan-DENV sequences was also
analyzed by assay of peptide-specific HLA-restricted T-cell responses
in murine H-2 class II-deficient, HLA-DR Tg mice expressing 3
prototypic HLA-DR alleles, corresponding to the divergent sub-
groups HLA-DR2 (DRB1*1501), HLA-DR3 (DRB1*0301), and
HLA-DR4 (DRB1*0401). Mice were immunized with pools of
overlapping peptides covering the sequences of the E, NS1, NS3, and
NS5 proteins of DENV-3, and HLA-DR-restricted CD4 T-cell
responses were assessed by IFN-c ELISpot assays using CD8-
depleted splenocytes. Thirty peptides eliciting positive T-cell
responses in the HLA Tg mice contained 9 or more consecutive
amino acids of 22 pan-DENV sequences, that were localized in the
NS5(11),NS3(6),NS1(4),andEproteins(one)(Table 5).Overall,9,
10 and 18 peptides elicited positive responses in HLA-DR2, -DR3,
and/or -DR4 Tg mice, respectively; 20 corresponded to sequences of
NS5, 10 of NS3, 6 of NS1, and one of E. Furthermore, at least 7 of
the pan-DENV sequences, all localized in the NS5 and NS1 proteins,
contained promiscuous T-cell determinants for multiple HLA-DR
alleles (Table 5). These data, together with those previously reported
(Table 4), showed that a minimum of 26 of the 44 pan-DENV
sequences, distributed predominantly in the NS5 and NS3 proteins,
and to a lesser extent in NS1 and E, contained numerous HLA-
restricted class II and/or class I determinants demonstrated by assays
of T-cell responses in vivo.
Discussion
In this study, we identified and characterized pan-DENV
sequences that were highly conserved in all recorded DENV
Figure 6. Number of Flaviviruses shared by the pan-DENV sequences.
doi:10.1371/journal.pntd.0000272.g006
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December 2007), and their wide distribution in terms of
geography and time (1945–2007) (data not shown), offered
information for a broad survey of DENV protein diversity in
nature. The 44 pan-DENV protein sequences of at least 9 aa,
covering 514 aa or about 15% of the complete DENV polyprotein
of ,3390 aa, were conserved in at least 80% of all recorded
DENV sequences, and 34 of the 44 (,77%) were conserved in
$95% of DENV sequences. All the 44 were in the non-structural
proteins except for the two E sequences. These conserved
sequences have shown remarkable stability over the entire history
of DENV sequences deposited in the NCBI Entrez protein
database, as illustrated by their low peptide entropy values and
variant frequencies. In addition, 27 of the pan-DENV sequences
were conserved in 64 other Flaviviruses, as further evidence of
prolonged evolutionary stability within this genus, as previously
discussed [59–61]. Two are also present in the proteomes of the
Aedes albopictus mosquito and the bacteria Chromohalobacter salexigens,
possibly in keeping with recent reports of the genetic recombina-
tion between phyla [58]. It is likely that these pan-DENV
sequences have been under selection pressure to fulfill critical
biological and/or structural properties, some of which have been
identified for the E (fusion peptide, dimerization domain), NS3
(peptidase S7, DEAD/H domains) and NS5 proteins (MTPase,
RdRp domains) [51–56]. Hence, these conserved sequences are
unlikely to significantly diverge in newly emerging DENV isolates
in the future, and represent attractive targets for the development
of specific anti-viral compounds and vaccine candidates.
There also is evidence that many of the conserved sequences are
immunologically relevant. A majority (26/44) contained at least 9
amino acids overlapping with a total of 45 peptides that have been
reported to be immunogenic in humans and/or HLA-DR Tg
mice. In addition, putative T-cell determinants for 12 major HLA
class I supertypes and for class II DR supertype, with broad
application to the immune responses of human population
worldwide, were predicted by computational analysis. Some of
the putative T-cell determinants were predicted to be promiscuous
to multiple HLA supertypes, in addition to multiple alleles of a
given HLA supertype. Such a degree of promiscuity has previously
been observed for DENV [62] and HIV peptides [63], among
others. The existence of conserved T-cell determinants specific for
multiple HLA supertypes further supports their evaluation as
vaccine targets, since they would provide broader population
coverage [63]. Many of the predicted HLA binding nonamers
were localized in clusters, as we have also observed in HLA Tg
mice immunized with WNV proteins and DNA encoding the
SARS coronavirus N protein [64], and has been reported in
studies of human immunodeficiency virus (HIV) type 1 proteins [65–68],
the outer membrane protein of Chlamydia trachomatis [69], and
other antigens [64].
The significant sequence variations between the proteins of the
4 DENV types represent a cardinal issue for the development of a
tetravalent DENV vaccine that provides robust protection against
each DENV type. Subtle amino acid substitutions within T-cell
determinants restricted by a given HLA allomorph, such as in the
event of sequential heterologous infections, or between a vaccine
formulation and a subsequent natural infection [7], can dramat-
ically alter the phenotype of the specific T cells, resulting in a wide
range of effects from agonism to antagonism [9,12–15]. Because of
the extent of intra-type (1 to 21%) and inter-type (14 to 67%)
amino acid variability among DENV isolates [48], many nonamer
T-cell determinants contain single or multiple amino acid
difference(s). When the 4 DENV types were analyzed together, a
majority of the nonamer positions across the full proteome
exhibited variants that together were present in ,60 to ,85% of
all sequences. The frequencies of variant peptides across the 4
DENV types suggest that vaccine strategies incorporating whole
DENV immunogens, such as inactivated and recombinant subunit
Table 4. Reported human T-cell determinants in the pan-DENV sequences.
DENV
protein Pan-DENV sequence
a Immunogenic T-cell determinants
b
Sequence
c T subset HLA Ag Reference(s)
E 252VLGSQEGAMH261 KKQDVVVLGSQEGAM - - [76]
NS3 46FHTMWHVTRG55 TFHTMWHVTRGAVLM CD4 - [76]
148GLYGNGVVT156 KVVGLYGNGVVTRSG CD4 DR*15 [76]
189LTIMDLHPG197 KRLTIMDLHPGAGKT CD4 - [72]
RKLTIMDLHPGSGKT CD4 - [72]
RKLTIMDLHPGAGKT CD4 - [72]
RNLTIMDLHPGSGKT CD4 - [72]
256EIVDLMCHATFT267 EHTGREIVDLMCHAT CD4 - [76]
EIVDLMCHATFTMRL CD4 - [76]
EIVDLMCHAT CD4 DPw2 [77,78]
284MDEAHFTDP292 LIIMDEAHFTDPASI - - [76]
313IFMTATPPG321 AGIFMTATPPGSRDP --[76]
357GKTVWFVPSIK367 TVWFVPSIK CD8 A*11 [16]
383VIQLSRKTFD392 KKVIQLSRKTFDSEY - - [76]
406VVTTDISEMGANF418 NDWDFVVTTDISEMG - - [76]
aAmino acid positions numbered according to the sequence alignments of the 4 DENV types
bDashes, not determined
cSequences present in the pan-DENV sequences are underlined
doi:10.1371/journal.pntd.0000272.t004
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structural DENV genes, are likely to elicit T-cell responses to
altered peptide ligands. This phenomenon is also likely to occur in
individuals exposed to several Flaviviruses, such as DENV, JEV and
YFV that are co-circulating in regions of Asia, India or South
America, or following vaccination [70].
While the immune correlates of DENV protection remain
poorly documented, there is evidence that both neutralizing
antibody and specific T-cell responses are required [7,71]. The
incorporation of defined HLA-restricted T-cell determinants
within DENV vaccine candidates might improve vaccine efficien-
cy by increasing T-cell help to sustain a robust, long-lived
Figure 7. Candidate putative HLA supertype-restricted, pan-DENV T-cell determinants predicted by computational algorithms.
Amino acid positions of the pan-DENV sequences are numbered according to the sequence alignments of the 4 DENV types; the corresponding DENV
proteins are indicated on the left. Predicted HLA-restricted T-cell determinants were identified using NetCTL, Multipred, ARB and TEPITOPE algorithms
(see Methods).
doi:10.1371/journal.pntd.0000272.g007
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effects on infected cells. For tetravalent formulations, it may be
relevant to focus primarily on sequences that are conserved in all
4 DENV types and to avoid the regions of T-cell immunity that
are highly variable, unless they are strictly type-specific [17,72].
The two pan-DENV E sequences (positions 97–111 and 252–
261) and the exposed domain III of the E antigen (positions 300–
400) [73,74], are also candidate sequences for neutralizing
antibody responses. An additional criterion for the selection of
T-cell targets is the need for determinants with broad HLA
representation, as it has been emphasized in the recognition of
HLA supertypes [18–20]. Further investigations are needed to
validate the immunogenicity of the candidate T-cell determinants
in human subjects, and to identify sequences associated with
deleterious T-cell responses.
The global approach described herein provides a framework and
methodology for large-scale and systematic analysis of conserved
sequences of other pathogens, in particular for rapidly evolving
viruses such as influenza A virus [75] and HIV [63]. These studies
will offer insights into their diversity and evolutionary history,
together with providing critical data for rational vaccine develop-
ment, structure-based design of candidate inhibitory compounds,
and improvement of the current diagnostic methods.
Supporting Information
Figure S1 Average nonamer peptide entropy for each protein of
each DENV type and all the four types combined. The values are
shown for the 2005 dataset.
Found at: doi:10.1371/journal.pntd.0000272.s001 (0.70 MB TIF)
Table 5. Immunogenicity of the pan-DENV sequences in HLA-DR transgenic mice.
DENV protein Pan-DENV sequence
b Ag-specific CD4 T-cell responses
a
Peptide sequences (DENV-3)
c IFN-c-SFC/10
6splenocytes6SD
d
DR2 DR3 DR4
E 252VLGSQEGAMH261 PEVVVLGSQEGAMHT - - 88634
NS1 193AVHADMGYWIES204 AVHADMGYWIESQKN - 1761-
229HTLWSNGVLES239 WPKSHTLWSNGVLES - 12963* -
HTLWSNGVLESDMII - 1316103 3763
266GPWHLGKLE274 HTQTAGPWHLGKLE - 33366-
294RGPSLRTTT302 TRGPSLRTTTVSGKL - - 1164
NS3 189LTIMDLHPG197 KKRNLTIMDLHPGSG - - 50616
296AARGYISTRV305 ASIAARGYISTRVGM 40614 - -
ARGYISTRVGMGEAA 964- -
313IFMTATPPG321 EAAAIFMTATPPGTA - - 4746116
IFMTATPPGTADAFP - - 3236287
357GKTVWFVPSIK367 TDFAGKTVWFVPSIK 48615 - -
GKTVWFVPSIKAGND 396614 - -
383VIQLSRKTFD392 KKVIQLSRKTFDTEY - 2163-
406VVTTDISEMGANF418 FVVTTDISEMGANFK - - 4086104
TDISEMGANFKADRV - 152633 -
NS5 302TWAYHGSYE310 DENPYKTWAYHGSYEVK 126610* - 1465
TWAYHGSYEVKATGSA 161620* - 63617
342AMTDTTPFGQQRVFKEKVDTRT363 MVTQMAMTDTTPFGQQR - - 2860*
450CVYNMMGKREKKLGEFG466 GSCVYNMMGKREKKLGE - - 1362
505SGVEGEGLH513 NSYSGVEGEGLHKLGYI - - 184615
531YADDTAGWDTRIT543 KIPGGAMYADDTAGWDT - - 4663
568IFKLTYQNKVV578 ANAIFKLTYQNKVVKVQ 5776384 - 2469*
597DQRGSGQVGTYGLNTFTNME616 VMDIISRKDQRGSGQVG - 8861-
658RMAISGDDCVVKP670 VERLKRMAISGDDCVVK - 159624 1666
MAISGDDCVVKPIDDRF - 249639 -
707VPFCSHHFH715 DWQQVPFCSHHFHELIM 3268* 34611 -
765LMYFHRRDLRLA776 MYFHRRDLRLASNAI 75616* - 3369
790PTSRTTWSIHA800 VHWVPTSRTTWSIHAHH - - 8361
SRTTWSIHAHHQWMTTE - - 122646
aAssessed by IFN-c ELISpot assay in HLA-DR2 (DRB1
*1501), HLA-DR3 (DRB1
*0301) and HLA-DR4 (DRB1
*0401) Tg mice immunized with DENV-3 peptides (see Methods)
bAmino acid positions numbered according to the sequence alignments of the 4 DENV types
cSequences present in the pan-DENV sequences are underlined
dSFC, spot-forming cells; SD, standard deviation. Representative results from at least two immunized Tg mice are shown, except when indicated by an asterisk
doi:10.1371/journal.pntd.0000272.t005
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www.plosntds.org 13 August 2008 | Volume 2 | Issue 8 | e272Figure S2 Molecular location of 19 pan-DENV sequences (in red)
on the protein’s 3-D structure. These sequences were mapped on the
available crystallographic models of the E ectodomain (PDB
Accession No. 1OAN; 394 out of 493-495 residues), NS3 (1BEF
and 2BMF, 181 and 451 out of 618-619 residues, respectively) and
NS5 fragments (1R6A, 295 out of 900-904 residues). The major
portions of eleven of the 19 pan-DENV sequences were buried
(NS3-148GLYGNGVVT156, 256EIVDLMCHATFT267,
284MDEAHFTDP292, 296AARGYISTRV305, 313IFMTATPPG321,
357GKTVWFVPSIK367, 406VVTTDISEMGANF418,a n d
491EAKMLLDNI499; NS5-79DLGCGRGGWSYY90,
141DTLLCDIGESS151 and 209PLSRNSTHEMYW220), 2 were
partially buried/exposed (NS3-46FHTMWHVTRG55 and
537LMRRGDLPVWL547) and the remaining 6 were exposed
(E-97VDRGWGNGCGLFGKG111 and 252VLGSQEGAMH261;
NS3-189LTIMDLHPG197 and 383VIQLSRKTFD392; NS5-6GETL-
GEKWK14 and 104TKGGPGHEEP113)a tt h es u r f a c eo ft h e
corresponding structures.
Found at: doi:10.1371/journal.pntd.0000272.s002 (9.65 MB
DOC)
Table S1 The intra-type percentage representation of pan-
DENV sequences.
Found at: doi:10.1371/journal.pntd.0000272.s003 (0.10 MB
DOC)
Table S2 Pan-DENV sequences, entropy and representation of
variants.
Found at: doi:10.1371/journal.pntd.0000272.s004 (0.08 MB
DOC)
Table S3 Functional and structural properties of pan-DENV
sequences.
Found at: doi:10.1371/journal.pntd.0000272.s005 (0.06 MB
DOC)
Table S4 Distribution of pan-DENV sequences in nature.
Found at: doi:10.1371/journal.pntd.0000272.s006 (0.12 MB
DOC)
Table S5 Candidate putative HLA supertype-restricted binding
nonamer peptides in pan-DENV sequences, predicted by
immunoinformatic algorithms.
Found at: doi:10.1371/journal.pntd.0000272.s007 (0.20 MB
DOC)
Table S6 Intra-type representation of candidate putative HLA
supertype-restricted nonamer peptides predicted by immunoinfor-
matics algorithms.
Found at: doi:10.1371/journal.pntd.0000272.s008 (0.22 MB
DOC)
Dataset S1 GI numbers.
Found at: doi:10.1371/journal.pntd.0000272.s009 (0.86 MB XLS)
Alternative Language Abstract S1 Translation of the abstract
into Chinese by Guang Lan Zhang.
Found at: doi:10.1371/journal.pntd.0000272.s010 (0.06 MB PDF)
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